Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE PanTumor: Phase 1b/2 Study of M9140 in Advanced Solid Tumors
jRCT2071240131Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of precemtabart tocentecan in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more, sponsored by Merck KGaA. Primary endpoint: Objective response rate (ORR) by RECIST v1.1 (GC/NSCLC/PDAC substudies). Started Apr 2025; status: active, not recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2071240131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240131.